Mechanisms of disease: mechanisms and clinical implications of cholestasis in sepsis

被引:175
作者
Geier, Andreas
Fickert, Peter
Trauner, Michael
机构
[1] Med Univ Graz, Div Gastroenterol & Hepatol, Dept Internal Med, A-8036 Graz, Austria
[2] Med Univ Graz, Intens Care Unit, A-8036 Graz, Austria
[3] Univ Aachen, Rhein Westfal TH Aachen, Dept Internal Med 3, Div Gastroenterol & Hepatol, Aachen, Germany
来源
NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY | 2006年 / 3卷 / 10期
关键词
cholangitis lenta; cholestasis; cytokines; sclerosing cholangitis; sepsis;
D O I
10.1038/ncpgasthep0602
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Cholestasis is a common complication in patients with extrahepatic bacterial infection and sepsis. This article gives a comprehensive overview of the molecular and cellular mechanisms of sepsis-associated cholestasis. Recent advances in the understanding of intrahepatic cholestasis have allowed us to delineate the molecular mechanisms that underlie sepsis-associated cholestasis and to describe their potential clinical and therapeutic applications. The mechanisms and clinical presentation of sepsis-associated liver injury vary according to the severity of the bacterial infection. Proinflammatory cytokines and nitric oxide cause cholestasis by impairing hepatocellular and ductal bile formation. Ischemic liver injury and, rarely, progressive sclerosing cholangitis can also be found in patients with septic shock, or major trauma with systemic inflammatory response syndrome. Treatment is mainly focused on eradication of the underlying infection and managing the sepsis. The use of ursodeoxycholic acid or extracorporeal liver support as treatments for sepsis-associated cholestasis is under investigation, but neither can be recommended in routine clinical practice at present. Patients with progressive sclerosing cholangitis should be considered for orthotopic liver transplantation.
引用
收藏
页码:574 / 585
页数:12
相关论文
共 89 条
[1]
Septic shock [J].
Annane, D ;
Bellissant, E ;
Cavaillon, JM .
LANCET, 2005, 365 (9453) :63-78
[2]
Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock [J].
Annane, D ;
Sébille, V ;
Charpentier, C ;
Bollaert, PE ;
François, B ;
Korach, JM ;
Capellier, G ;
Cohen, Y ;
Azoulay, E ;
Troché, G ;
Chaumet-Riffaut, P ;
Bellissant, E .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (07) :862-871
[3]
Molecular aspects of bile formation and cholestasis [J].
Arrese, M ;
Trauner, M .
TRENDS IN MOLECULAR MEDICINE, 2003, 9 (12) :558-564
[4]
Bench-to-bedside review: Microvascular dysfunction in sepsis - hemodynamics, oxygen transport, and nitric oxide [J].
Bateman, RM ;
Sharpe, MD ;
Ellis, CG .
CRITICAL CARE, 2003, 7 (05) :359-373
[5]
Benninger J, 2005, WORLD J GASTROENTERO, V11, P4199
[6]
Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis [J].
Beuers, Ulrich .
NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY, 2006, 3 (06) :318-328
[7]
EFFECT OF INDUCED FEVER ON SULFOBROMOPHTHALEIN KINETICS IN MAN [J].
BLASCHKE, TF ;
ELIN, RJ ;
BERK, PD ;
SONG, CS ;
WOLFF, SM .
ANNALS OF INTERNAL MEDICINE, 1973, 78 (02) :221-226
[8]
Bochud Pierre-Yves, 2004, Crit Care Med, V32, pS495, DOI 10.1097/01.CCM.0000143118.41100.14
[9]
Inhibition of transport across the hepatocyte canalicular membrane by the antibiotic fusidate [J].
Bode, KA ;
Donner, MG ;
Leier, N ;
Keppler, D .
BIOCHEMICAL PHARMACOLOGY, 2002, 64 (01) :151-158
[10]
DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ .
CHEST, 1992, 101 (06) :1644-1655